Rotavirus Inner Capsid VP6 Acts as an Adjuvant in Formulations with Particulate Antigens Only
Novel adjuvants present a concern for adverse effects, generating a need for alternatives. Rotavirus inner capsid VP6 protein could be considered a potential candidate, due to its ability to self-assemble into highly immunogenic nanospheres and nanotubes. These nanostructures exhibit immunostimulatory properties, which resemble those of traditional adjuvants, promoting the uptake and immunogenicity of the co-administered antigens. We have previously elucidated an adjuvant effect of VP6 on co-delivered norovirus and coxsackievirus B1 virus-like particles, increasing humoral and cellular responses and sparing the dose of co-delivered antigens. This study explored an immunostimulatory effect of VP6 nanospheres on smaller antigens, P particles formed by protruding domain of a norovirus capsid protein and a short peptide, extracellular matrix protein (M2e) of influenza A virus. VP6 exhibited a notable improving impact on immune responses induced by P particles in immunized mice, including systemic and mucosal antibody and T cell responses. The adjuvant effect of VP6 nanospheres was comparable to the effect of alum, except for induction of superior mucosal and T cell responses when P particles were co-administered with VP6. However, unlike alum, VP6 did not influence M2e-specific immune responses, suggesting that the adjuvant effect of VP6 is dependent on the particulate nature of the co-administered antigen.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
---|---|
Enthalten in: |
Vaccines - 8(2020), 3 vom: 07. Juli |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Heinimäki, Suvi [VerfasserIn] |
---|
Links: |
---|
Themen: |
Adjuvant |
---|
Anmerkungen: |
Date Revised 27.10.2020 published: Electronic Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.3390/vaccines8030365 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM312227760 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM312227760 | ||
003 | DE-627 | ||
005 | 20231225143947.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/vaccines8030365 |2 doi | |
028 | 5 | 2 | |a pubmed24n1040.xml |
035 | |a (DE-627)NLM312227760 | ||
035 | |a (NLM)32645976 | ||
035 | |a (PII)E365 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Heinimäki, Suvi |e verfasserin |4 aut | |
245 | 1 | 0 | |a Rotavirus Inner Capsid VP6 Acts as an Adjuvant in Formulations with Particulate Antigens Only |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 27.10.2020 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a Novel adjuvants present a concern for adverse effects, generating a need for alternatives. Rotavirus inner capsid VP6 protein could be considered a potential candidate, due to its ability to self-assemble into highly immunogenic nanospheres and nanotubes. These nanostructures exhibit immunostimulatory properties, which resemble those of traditional adjuvants, promoting the uptake and immunogenicity of the co-administered antigens. We have previously elucidated an adjuvant effect of VP6 on co-delivered norovirus and coxsackievirus B1 virus-like particles, increasing humoral and cellular responses and sparing the dose of co-delivered antigens. This study explored an immunostimulatory effect of VP6 nanospheres on smaller antigens, P particles formed by protruding domain of a norovirus capsid protein and a short peptide, extracellular matrix protein (M2e) of influenza A virus. VP6 exhibited a notable improving impact on immune responses induced by P particles in immunized mice, including systemic and mucosal antibody and T cell responses. The adjuvant effect of VP6 nanospheres was comparable to the effect of alum, except for induction of superior mucosal and T cell responses when P particles were co-administered with VP6. However, unlike alum, VP6 did not influence M2e-specific immune responses, suggesting that the adjuvant effect of VP6 is dependent on the particulate nature of the co-administered antigen | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a M2e | |
650 | 4 | |a P particle | |
650 | 4 | |a VP6 | |
650 | 4 | |a adjuvant | |
650 | 4 | |a alum | |
650 | 4 | |a nanostructure | |
650 | 4 | |a peptide | |
700 | 1 | |a Tamminen, Kirsi |e verfasserin |4 aut | |
700 | 1 | |a Hytönen, Vesa P |e verfasserin |4 aut | |
700 | 1 | |a Malm, Maria |e verfasserin |4 aut | |
700 | 1 | |a Blazevic, Vesna |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Vaccines |d 2012 |g 8(2020), 3 vom: 07. Juli |w (DE-627)NLM239212347 |x 2076-393X |7 nnns |
773 | 1 | 8 | |g volume:8 |g year:2020 |g number:3 |g day:07 |g month:07 |
856 | 4 | 0 | |u http://dx.doi.org/10.3390/vaccines8030365 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 8 |j 2020 |e 3 |b 07 |c 07 |